Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AFFYMETRIX (AFFX) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (1607)	3/27/2003 11:01:49 AM
From: tuck	Read Replies (1) \| Respond to of 1728

>>9:41AM Affymetrix cut to Equal Weight from Overweight at ThinkEquity (AFFX) 27.27 -0.53: Firm cites valuation and potential risk to GeneChip sales until new genotyping and diagnostic applications kick-in. Notes in recent channel checks, no customers were bullish about ordering patterns and there is clearly concern that co will miss the qtr circulating around Wall Street.<< This follows a JP Morgan downgrade a day or two ago for similar reasons, chiefly valuation.<< Cheers, Tuck